alexa Polymer ?ruthenium-cyclopentadienyl? Conjugates: A New Approach To Fight Cancer
ISSN: 2161-0444

Medicinal chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing
December 08-10, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Andreia Valente, M Helena Garcia, Leonor C?rte-Real, Guilherme Nogueira, Philippe Zinck, Ant?nio Matos and Fernanda Marques
ScientificTracks Abstracts: Med Chem
DOI: 10.4172/2161-0444.S1.011
Abstract
The continuous rising of cancer patients? death rate undoubtedly shows the pressure to find more potent and efficient drugs than those in clinical use, mainly based in platinum. These agents only treat a narrow range of cancer conditions with limited success and are associated with serious side effects caused by the lack of selectivity. The ideal situation is to have a drug that is only delivered to the tumor without affecting the healthy tissues. In this frame, our research group has recently published the synthesis and preliminary biological activity against several cancer lines of a new high molecular weight ruthenium-polymer complex.This conjugate incorporates a tumor-specific molecule attached to the polymeric chain and a cytotoxic fragment based on the ?Ru-cyclopentadienyl? core, which presents high cytotoxic activity in several human cancer cell lines. The important potential of this family of polymer-ruthenium conjugates has been also revealed by studies of cellular uptake, molecular targets determination and pH-dependent release of the cytotoxic moiety. Our approach is different of those already reported in the literature, and we expect that it will lead to different reactivity patterns and thus a different model of behavior. Within the present presentation we will unveil possible targets and mechanism of action of this new family of ruthenium-polymer conjugates.
Biography
Andreia Valente completed her PhD in 2010 from the Universit? de Lille I (France) on the field of Polymerization Catalysis. Then, she joined the Organometallic Group at Faculty of Sciences, University of Lisbon (Portugal) where she got a first post-doc position in synthesis of organometallic compounds for nonlinear optic applications, followed by a second post-doc in the field of medicinal inorganic chemistry. She is presently a researcher (academic) at the same Institution, directing now her efforts to the synthesis of new polymer-metal complexes as targeted drug-delivery systems in view to cancer therapy.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords